News Snapshot:
BEIJING (China Daily/Asia News Network): Two Covid-19 antibody drugs developed in China have yielded promising results in studies and clinical trials, researchers said during an academic conference over the weekend. Professor Zhang Linqi at Tsinghua University's School of Medicine said on Sunday (Nov 21) that a domestically developed cocktail therapy of monoclonal antibodies BRII-196 and BRII-198 has shown an efficacy rate of 78 per cent in cutting hospitalisations and deaths among high-risk groups in late-stage clinical trials. The treatment has been jointly developed by his team at Tsinghua, the Third People's Hospital of Shenzhen, Guangdong province, as well as biotech...
